- Home
- PUBM vs TERN Comparison
PUBM vs TERN Comparison
Compare PUBM & TERN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PUBM
- TERN
- Stock Information
- Founded
- PUBM 2006
- TERN 2017
- Country
- PUBM United States
- TERN United States
- Employees
- PUBM N/A
- TERN N/A
- Industry
- PUBM Computer Software: Prepackaged Software
- TERN Biotechnology: Pharmaceutical Preparations
- Sector
- PUBM Technology
- TERN Health Care
- Exchange
- PUBM Nasdaq
- TERN Nasdaq
- Market Cap
- PUBM 576.6M
- TERN 531.9M
- IPO Year
- PUBM 2020
- TERN 2021
- Fundamental
- Price
- PUBM $11.12
- TERN $5.47
- Analyst Decision
- PUBM Buy
- TERN Buy
- Analyst Count
- PUBM 11
- TERN 5
- Target Price
- PUBM $22.60
- TERN $15.63
- AVG Volume (30 Days)
- PUBM 532.6K
- TERN 1.0M
- Earning Date
- PUBM 08-11-2025
- TERN 08-12-2025
- Dividend Yield
- PUBM N/A
- TERN N/A
- EPS Growth
- PUBM N/A
- TERN N/A
- EPS
- PUBM 0.10
- TERN N/A
- Revenue
- PUBM $288,380,000.00
- TERN N/A
- Revenue This Year
- PUBM $2.80
- TERN N/A
- Revenue Next Year
- PUBM $10.43
- TERN N/A
- P/E Ratio
- PUBM $112.60
- TERN N/A
- Revenue Growth
- PUBM 3.62
- TERN N/A
- 52 Week Low
- PUBM $7.46
- TERN $1.87
- 52 Week High
- PUBM $22.25
- TERN $11.40
- Technical
- Relative Strength Index (RSI)
- PUBM 37.27
- TERN 56.99
- Support Level
- PUBM $11.94
- TERN $5.57
- Resistance Level
- PUBM $12.84
- TERN $6.10
- Average True Range (ATR)
- PUBM 0.49
- TERN 0.28
- MACD
- PUBM -0.19
- TERN -0.06
- Stochastic Oscillator
- PUBM 0.00
- TERN 41.04
About PUBM PubMatic Inc.
PubMatic Inc is a supply-side platform provider in the digital advertising technology market. These platforms help publishers, which supply digital ad inventory, manage their inventory, selling a high percentage of their inventory (increase the ad fill rate) and maximizing revenue per ad sold (optimize yield). The company generates revenue mainly by taking a piece of the ad sales that it enables. Buyers on the platform include intermediary buyers, such as demand-side platforms, or advertisers and ad agencies directly. Geographically, the company generates the majority of its revenue from the United States, followed by EMEA and APAC.
About TERN Terns Pharmaceuticals Inc.
Terns Pharmaceuticals Inc is a clinical-stage biopharmaceutical company. The company is developing a portfolio of small-molecule single-agent and combination therapy candidates for the treatment of non-alcoholic steatohepatitis, NASH, and other chronic liver diseases. Its product candidates include TERN-701, TERN-601, TERN-501 and TERN-800.